Geron Co. (NASDAQ:GERN – Get Rating) saw a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 23,610,000 shares, an increase of 5.3% from the April 15th total of 22,420,000 shares. Based on an average daily trading volume, of 5,430,000 shares, the days-to-cover ratio is […]
Geron Co. (NASDAQ:GERN – Get Rating) Director V Bryan Lawlis sold 35,000 shares of the firm’s stock in a transaction on Thursday, May 11th. The stock was sold at an average price of $3.00, for a total value of $105,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through […]
Geron (NASDAQ:GERN – Get Rating) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.02, RTT News reports. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.14 million. Geron had a […]
Needham & Company LLC reissued their buy rating on shares of Geron (NASDAQ:GERN – Get Rating) in a research note published on Friday, Benzinga reports. Needham & Company LLC currently has a $4.00 price target on the biopharmaceutical company’s stock. Other equities research analysts have also issued reports about the company. Wedbush restated an outperform […]
Geron Co. (NASDAQ:GERN – Get Rating)’s share price dropped 3.8% on Thursday . The company traded as low as $2.35 and last traded at $2.40. Approximately 1,230,778 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 8,539,026 shares. The stock had previously closed at $2.49. Analyst Upgrades and […]